Home > Healthcare > Medical Devices > Diagnostic Devices > Autoimmune Disease Diagnostics Market

Autoimmune Disease Diagnostics Market Size

  • Report ID: GMI618
  • Published Date: Sep 2024
  • Report Format: PDF

Autoimmune Disease Diagnostics Market Size

Autoimmune Disease Diagnostics Market size was valued at USD 5.3 billion in 2023 and is anticipated to witness growth at a CAGR of 5.9% between 2024 and 2032. The rising incidence of autoimmune diseases and the adoption of automation in equipment are vital factors propelling global market growth.

 

Autoimmune disorders develop when the immune system mistakenly attacks its own cells due to abnormalities. A failure to detect immune cells, tissues, and organs, coupled with the production of autoantibodies targeting these cells, causes the immune system to malfunction. Consequently, several initiatives by organizations aim to raise awareness about autoimmune diseases and their socioeconomic impact, thereby increasing the usage rates of autoimmune disease diagnostics globally. Additionally, improved laboratory automation and technological advancements in diagnostics are driving the expansion of the autoimmune disease diagnostics market.
 

Autoimmune diseases are conditions where the immune system attacks one or more normally functioning cells in the body due to asymmetry or irregularities. This malfunction is primarily caused by the immune system's inability to recognize tissues, immunological cells, and other organs, leading to the production of autoantibodies against these cells.
 

However, the need for high capital investment in setting up diagnostic centers, slow turnaround times for test results, and the requirement for multiple diagnostic tests can adversely affect market growth. Diagnostic centers for autoimmune diseases face stringent government regulations and diagnostic complications that may negatively impact business expansion. Various blood tests, such as C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), enzyme-linked immunosorbent assay (ELISA), and rheumatoid factor (RF), are used to detect the type and severity of autoimmune diseases.

Authors: Mariam Faizullabhoy , Gauri Wani

Frequently Asked Questions (FAQ) :

The autoimmune disease diagnostics industry was valued at USD 5.3 billion in 2023 and is anticipated to witness 5.9% CAGR from 2024 to 2032, led by rising incidence of autoimmune diseases and the adoption of automation in equipment

The hospitals end-use segment accounted for 53.5% of the market share in 2023 owing to the surged adoption of autoimmune disease diagnostic procedures in hospitals associated to complex interventional surgeries.

North America autoimmune disease diagnostics industry size was USD 1.9 billion in 2023 attributed to rising autoimmune disease burden, and increasing healthcare expenditure

Abbott Laboratories, Bio-Rad Laboratories, Inc., DIAsource ImmunoAssays SA, Euroimmun AG (Perkin Elmer), F. Hoffmann-la Roche Ltd., Hemagen Diagnostics, Myriad Genetics, Quest Diagnostics, Siemens Healthineers Inc., SQI Diagnostics Inc., and Thermo Fisher Scientific Inc.

Autoimmune Disease Diagnostics Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 12
  • Tables & Figures: 234
  • Countries covered: 24
  • Pages: 190
 Download Free Sample